ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
203 citing papers in PubMed, 1 synthesis or guideline pooled it, 289 citations in OpenAlex.
- Analysis from the perspective of cilia: the protective effect of PARP inhibitors on visual function during light-induced damage.International ophthalmology · 2020Pooled it
- Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.Proceedings of the National Academy of Sciences of the United States of America · 2026Trial
- The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.Nature communications · 2024Trial
- Trial
- Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.Gynecologic oncology · 2021Trial
- Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).JCO precision oncology · 2021Trial
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.British journal of cancer · 2026Article
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies.International journal of molecular sciences · 2026Review
- RMI2 knockdown suppresses ovarian cancer cell growth by impairing DNA damage repair via the ATR/CHK1 signaling pathway.In vitro cellular & developmental biology. Animal · 2026Article
- PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.The Journal of clinical investigation · 2026Article
- Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.International journal of molecular sciences · 2026Review
- Tilting the balance of life and death: navigating DNA replication stress in cancer therapy.Experimental & molecular medicine · 2026Review
- Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer.British journal of cancer · 2026Article
- Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.British journal of cancer · 2026Article
- Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.Cancer research · 2026Article
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
- Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair.Molecular cancer · 2026Review
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Hyoung Kim *Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.
Erin George *Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.
Ryan RaglandCancer Biology, University of Pennsylvania, Philadelphia, PA.
Stavros RafailPenn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.
Rugang ZhangWistar Institute, Philadelphia, PA.
Clemens KreplerWistar Institute, Philadelphia, PA.
Mark MorganPenn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.
Meenhard HerlynWistar Institute, Philadelphia, PA.
Eric BrownCancer Biology, University of Pennsylvania, Philadelphia, PA.
Fiona SimpkinsPenn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.
University of Pennsylvania · USThe Wistar Institute · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MRole of BRCA1 Pathway in Regulating Oncogene-Induced SenescenceR01CA160331 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$4.0MTargeting EZH2 in CARM1-expressing epithelial ovarian cancerR01CA163377 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$3.7MThe role of ATR in preventing age-related diseasesR01AG027376 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BROWN, ERIC J · 2006 to 2015
$3.2MEffects of ATR-CHK1 inhibition on genome stability and cancer progressionR01CA189743 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BROWN, ERIC J · 2015 to 2019
$1.8MTargeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian CancerK08CA151892 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SIMPKINS, FIONA · 2011 to 2016
$807kNCI NIH HHS K08 CA151892NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA160331NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA189743NCI NIH HHS R01 CA202919NIA NIH HHS R01 AG027376
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinCell Line, TumorCell ProliferationCheckpoint Kinase 1Drug SynergismFemaleGenomic InstabilityHumansIndolesMiceMolecular Targeted TherapyMorpholinesOvarian NeoplasmsAtaxia Telangiectasia Mutated ProteinsATR protein, humanBRCA1 ProteinBRCA1 protein, humanceralasertibCheckpoint Kinase 1CHEK1 protein, humanIndolesMK-8776MorpholinesolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPyrazolesPyrimidinesSulfonamidesSulfoxides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.